In addition to CTLA‐4 and PD‐1, we utilized the cMAP datasets to explore the potential therapeutic drugs targeting the high‐risk glioma, and we got 20 prospective drugs with a significant score for glioma treatment including 5,182,598, exisulind, MG‐262, etc. (Table S22; enrichment <−0.5, p < 0.05). This evidence concerns the gene CTLA4 and central nervous system cancer.